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Abstract: Photodynamic therapy relies on the bioavailability of photosensitizers with suitable photophysical, chemical and 
biochemical properties. Although the photophysical properties, stability and high water solubility of the chromium(III) complex 
[Cr(ddpd)2][BF4]3 (ddpd = N,N’-dimethyl-N,N’-dipyridin-2-ylpyridine-2,6-diamine) are very favorable, its photocytotoxicity 
against cancerous and non-cancerous cell lines has not yet been elucidated. We now report the cytotoxicity and 
photocytotoxicity of the complex [Cr(ddpd)2][BF4]3 against human cervical cancer cells, human primary glioblastoma cells, 
human glioblastoma astrocytoma cells and non-cancerous retinal pigment epithelium cells. 
Introduction 
Photodynamic therapy (PDT) is an approved medical technique that requires the combination of three individually non-
toxic components to induce cellular and tissue effects, namely a photosensitizer (PS), oxygen and light.[1,2] Typically, the 
PS is a photosensitive molecule that localizes to a target cell and/or tissue. Following the absorption of light, a typically 
employed PS such as Photofrin® [3] is transformed from its singlet ground state into a relatively long lived excited triplet 
state via a short lived excited singlet state followed by intersystem crossing. During its lifetime, the excited triplet state 
can undergo different reactions, namely direct reaction with a substrate, such as cell membrane components or other 
biologically important molecules to form radicals (photoredox reaction) or, alternatively, triplet oxygen can quench the 
excited triplet state forming singlet oxygen (energy transfer). Both these reactions occur close to the light absorbing PS. 
Consequently, the biological response to the PS evolves only in those areas of tissue that have been exposed to light. 
This mechanism accounts for the fact that side effects of PDT are generally much less severe than those of 
“conventional” chemotherapy.  
Despite all advantages of PDT, the currently employed PDT PSs are not ideal in every respect. Current challenges 
comprise tedious synthetic procedures of the photosensitizer, employment of critical elements such as noble metals or 
rare earth elements, dye aggregation due to π stacking, poor drug clearance that leads to prolonged photosensitivity in 
patients, poor drug solubility in aqueous solution or poor targeting ability.[4,5] Metal complexes with their broad structural 
and chemical diversity are suitable drug alternatives, as demonstrated by some of us and others.[6-13] While most of the 
typically employed dyes are complexes of the second and third row transition metal ions or lanthanide ions, or 
elaborated organic molecules, it is challenging to achieve long-lived phosphorescent excited states with first-row 
transition metal complexes. Moreover, many emitters efficiently decay to the ground state by a multitude of non-
radiative pathways, such as low-energy dark excited states, energy transfer to high energy oscillators, excimer 
formation or direct surface crossing to the ground state.[14-16] Such effects reduce the excited state lifetime inhibiting 
efficient bimolecular reactions with (biological) substrates. Beyond PDT, emissive dyes have found numerous 
applications in organic light emitting diodes, telecommunication, night vision readable displays, oxygen sensing, singlet 
oxygen formation, and in vivo imaging among others.[17-26]  
 
 
 
Scheme 1. Molecular structure of the chromium(III) complex [Cr(ddpd)2][BF4]3 and its key properties relevant to photodynamic therapy (PDT). 
The excited state lifetimes of first row transition metal complexes are typically extremely short[14] and only recently a few 
ground-breaking complexes have been identified apart from copper(I) complexes.[27-31] A key to increase the excited 
state lifetime of 3d metal complexes is to increase the ligand field splitting. Octahedral chromium(III) ions are suitable 
candidates as phosphorescent emitters with long excited state lifetimes. However, typical phosphorescence quantum 
yields for such Cr complexes are rather low (< 0.15 %).[32] Yet, photoredox catalysis using [Cr(phen)3]3+ derivatives 
proved successful confirming a suitable excited state lifetime.[33-35] Widening the N-Cr-N bite angle close to 90° and 
concomitant increasing of the ligand field splitting led to the complex [Cr(ddpd)2]3+ with exceptionally favorable 
photophysical properties (ddpd = N,N’-dimethyl-N,N’-dipyridin-2-ylpyridine-2,6-diamine[36]; Scheme 1).[31,37] The lifetime 
of the excited doublet state (2E) of [Cr(ddpd)2]3+ amounts to 898 µs in water and the corresponding quantum yield to 11 
% in the absence of O2.[31] These photophysical properties led to the notion of [Cr(ddpd)2]3+ complexes as “molecular 
ruby”.[31,37,38] Deuteration of the solvent and the ligand even increases the quantum yield to 30 % and the lifetime to 
more than 2 ms.[38]  
Oxygen quenches this emission with a bimolecular rate constant kq = 1.77×107 M–1 s–1 and a Stern-Volmer constant KSV 
= 1.59×104 M–1.[31] In fact, singlet oxygen (1O2) forms due to energy transfer from the excited 2E state of the 
chromium(III) complex to 3O2 with 61 % quantum yield in DMF.[39] This feature of the chromium(III) complex has already 
been exploited in photocatalytic reactions of [Cr(ddpd)2]3+ and oxygen.[39] On the other hand, photoredox chemistry of 
this complex is not observed and its excited state reactivity is solely based on energy transfer reactions. The complex 
[Cr(ddpd)2][BF4]3 is highly water soluble.[31] Furthermore, the cation [Cr(ddpd)2]3+ is substitutionally stable both at neutral 
and at high pH in the dark in contrast to e.g. [Cr(tpy)2]3+.[31,40] Even under irradiation with 430 nm LEDs at pH 7 and at 
pH 11.4 no photodecomposition is observed for at least 5 h, in contrast to other typical chromium(III) complexes such as 
[Cr(bpy)3]3+, which undergo photosubstitution.[31,37] The very favorable chemical and photophysical properties of 
[Cr(ddpd)2][BF4]3, namely high excited state lifetime, high singlet oxygen quantum yield under irradiation, high water 
solubility and high photostability, prompted us to explore the potential of this chromium(III) complex as PS in PDT 
applications against cancer cell lines.  
Chromium, specifically in its trivalent state is reported as an essential trace element and small amounts are beneficial 
for improving blood-sugar levels for patients suffering from prediabetes or type 1 and type 2 diabetes. It is also used for 
depression, Turner’s syndrome, polycystic ovary syndrome, lowering "bad" cholesterol, raising "good" cholesterol in 
people taking heart medications called beta blockers, metabolic syndrome and heart attack. Some people even try 
chromium(III) for body conditioning including weight loss, increasing muscle, and decreasing body fat. Chromium is also 
suggested to improve athletic performance, to increase energy, and to prevent age-related mental decline. The 
absorption of chromium is less than 2% in the intestines and chromium picolinate is used as a supplement.[41-43] 
Chromium(III) complexes show effects against different bacterial strains like S. aureus and E. coli[44] and further studies 
report the potential of such complexes against human dermal fibroblasts.[45] As a serious note of caution, Lay and co-
workers have demonstrated that chromium(III) complexes with labile ligands can be transformed to carcinogenic 
chromium(VI) species in adipocytes.[46] We note also that organometallic chromium(0) complexes have been used for 
medicinal applications.[47-49] To the best of our knowledge, photocytotoxicity studies of chromium(III) complexes have not 
yet been reported.  
The present study reports the stability of [Cr(ddpd)2][BF4]3 in biological media, its cytotoxicity and its photocytotoxicity for 
use as a potential PDT PS against cancer cell lines. 
Results and Discussion 
Human Plasma Stability. Based on the favorable stability of [Cr(ddpd)2]3+ cations in organic and aqueous media,[31] we 
extended these stability tests to a biological medium, specifically human plasma. The stability of the complex in human 
plasma was checked at different time intervals using an adapted method performed previously for other complexes by 
some of us.[11] We incubated the complex in human plasma for 4 h, 24 h, and 48 h at 37 °C and assessed its stability 
using high performance liquid chromatography (HPLC). Caffeine was used an internal control since it is known to be 
stable in these conditions. The data displayed in Figure 1 confirm the high stability under these experimental conditions 
indicating its suitability as a PDT PS. 
 
 
Figure 1. Ratio of [Cr(ddpd)2]
3+ to caffeine (internal standard) at different time intervals (0 h, 4 h, 24 h, 48 h) in human plasma. 
 
Cytotoxicity and Photocytotoxicity. Cytotoxicity and photocytotoxicity of [Cr(ddpd)2][BF4]3 were evaluated using 
human cervical cancer cells (HeLa), human primary glioblastoma cells (U87), human glioblastoma astrocytoma cells 
(U373 MG) and non-cancerous retinal pigment epithelium (RPE-1) cells. After 4 h incubation with the complex in the 
respective culture medium of the cell lines at different concentration and exchange of the comlex-containing medium 
against Cr-free medium the cells were irradiated with 450 nm LEDs (10 mins, 7.6 J cm–2). Control experiments were 
conducted in the dark. Without irradiation, [Cr(ddpd)2]3+ is only weakly cell-toxic with IC50 values of around 200 µM for all 
cancer cells. Upon light irradiation, the cytotoxicity of the complex increased only fivefold (i.e. photocytotoxicity index PI 
= 5) (Figure 2 and Table 1). Considering the luminescence quantum yield, the excited state lifetime and the 1O2 
quantum yield of [Cr(ddpd)2]3+ a markedly higher PI was anticipated.[31,39] Possibly, cellular internalization of 
[Cr(ddpd)2]3+ is insufficient and consequently, the incubation time was extended to 24 h. Yet, this measure did not 
increase the photocytotoxicity index (Table 1). To test the hypothesis that the water-soluble complex displays only poor 
cellular internalization, we checked its luminescence in cells using confocal microscopy. Despite several attempts at 
high complex concentration up to 250 µM, luminescence of the cells could not be detected by the confocal microscope.  
 
 
 
 
 
Figure 2. (a) Photocytotoxicity of [Cr(ddpd)2)][BF4]3 after 4 h incubation in different cell lines with irradiation at 450 nm, 10 mins, 7.6 J cm
–2 (blue) 
or in the dark (black). (b) Photocytotoxicity index of the complex in HeLa, U87 and U353MG cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Possibly, the trication [Cr(ddpd)2]3+ is unable 
to cross cell membranes. This could be due to its high charge and consequently poor lipophilicity. To support this 
assumption, we investigated the ion paring properties of [Cr(ddpd)2][BF4]3 and the lipophilicity. 
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Table 1. IC50 values of [Cr(ddpd)2)][BF4]3 in different cell lines with and 
without irradiation. 
Cell line  IC50 (450 nm)
 [a] / 
µM 
IC50 (dark)/ µM
  Photo-
cytotoxicity 
index (PI) 
HeLa 38.4±1.2 (39.8± 
1.9) 
199.5±1.2 
(202.8±1.1) 
5.2 
U87 47.0±1.7 (45.1± 
2.2) 
207.4±4.7 
(215.9±3.1) 
4.4 
U373MG 44.8±3.6 (46.9± 
2.5) 
201.2±5.5 
(202.1±3.9) 
4.5 
RPE-1 89.2±3.2 (82.2±4.2) > 250 (> 250) ND 
[a] Dose of irradiation was 7.6 J cm–2, 10 mins. Values in parenthesis 
indicate IC50 values obtained after 24 h incubation with [Cr(ddpd)2][BF4]3. ND 
indicates not determined 
Lipophilicity Measurements (Log P). To obtain an insight into the poor cellular uptake behavior of the [Cr(ddpd)2]3+ 
complex, we evaluated its lipophilicity from its partition coefficient in a PBS-octanol system. Ferrocene was used as a 
reference. Under identical experimental conditions, the chromium(III) complex had a lipophilicity value of –1.1 while that 
for the ferrocene was 1.4. This clearly indicates that the compound is very hydrophilic and this probably leads to a poor 
cellular uptake. This can certainly account for the very modest cytotoxicity values observed. 
 
Conductivity. In order to obtain an impression of the effective charge of the chromium(III) salt [Cr(ddpd)2][BF4]3 in 
solution, its conductivity in CH3CN solution was determined. Its experimentally determined equivalent conductivity 
amounts to Λ0 = 263 S cm–1 M–1. This conductivity is larger than for the 1:1 electrolyte [nBu4N][BF4] with Λ0 = 177 S cm–1 
M–1 (Figure 3) but lower than that of typical 1:3 electrolytes with Λ0 = 340 – 420 S cm–1 M–1.[50] Hence under these 
conditions, [Cr(ddpd)2][BF4]3 behaves as a 1:2 electrolyte and the average charge of the ion pairs {[Cr(ddpd)2][BF4]n}3-n 
amounts to 2+. Similar charge values are expected in water or plasma. Obviously, reduction of the high positive charge 
of 3+ of the chromium(II) complex to 2+ due to counter ion association is insufficient to allow this complex ion pair to 
cross cell membranes efficiently. Hence, other strategies such as increasing the lipophilicity by suitable substituents, 
conjugation with cell penetrating peptides[51] or reduction of the overall complex charge have to be devised to allow this 
complex entering cells. 
 
 
Figure 3. Conductivity measurements of [Cr(ddpd)2][BF4]3 and the 1:1 electrolyte reference [
nBu4N][BF4] in CH3CN. 
Conclusions 
This study describes the (photo-)cytotoxic properties of the water soluble, stable, luminescent chromium(III) complex 
[Cr(ddpd)2][BF4]3. In the dark, [Cr(ddpd)2][BF4]3 is essentially non-toxic to various cell lines. Although [Cr(ddpd)2][BF4]3 is 
able to form singlet oxygen from triplet oxygen under light irradiation, its phototoxic index is relatively poor. 
Consequently, [Cr(ddpd)2][BF4]3 is unsuitable as photosensitizer for photodynamic therapy. The poor performance has 
been ascribed to the insufficient internalization of the complex cation into the cell. Although, ion paring reduces the 
overall charge somewhat, the lipophilicity and cell permeability are obviously too low for efficient cellular accumulation.  
In the future, we aim to modify the chromium(III) complex by decreasing the overall positive charge and/or decorating 
with hydrophobic groups on the ligand periphery to improve the cellular uptake and enable its use as a PDT PS. 
Experimental Section 
Materials. Dulbecco’s Modified Eagles Medium (DMEM, catalogue number 11500416), Dulbecco’s Modified Eagles 
Medium supplemented with nutrient mixture F-12 (DMEM/ F-12, catalogue number 11580546), fetal bovine serum 
(FBS, catalogue number 11573397), Gibco™ Penicillin-Streptomycin-Glutamine (penstrep, catalogue number 
12090216), Gibco™ MEM Non-Essential Amino Acids Solution (catalogue number 11140050, Dulbecco’s Phosphate-
Buffered Saline (DPBS, catalogue number 12559069), Trypsin-EDTA (catalogue number 11560626) and resazurin 
(catalogue number 10751244 were purchased from Fisher Scientific. [Cr(ddpd)2][BF4]3 was synthesized as previously 
described.[31] 
 
Cell culture. HeLa cells were cultured in DMEM, RPE-1 cells were cultured in DMEM/ F-12, U87 and U373MG cells 
were cultured in MEM media having 1% NEAA and reconstituted with 10% FBS and 1% penstrep. Cells were grown in a 
humidified cell culture incubator at 37 °C and with 5% CO2 and passaged three times before using for the experiments. 
 
 
Stability Studies in human plasma. Stability study of the complex in human plasma was performed by a slightly 
modified method. [11] Caffeine was obtained from TCI chemicals and used as the internal standard. The human plasma 
was procured from Fischer Scientific (Gibco). For each experiment, fresh stock solutions of the complex (1.0 mM), and 
caffeine (1.0 mM) were prepared in DMSO and protected from light. Final concentration of the complex and caffeine in 
plasma was 50 µM and 20 µM respectively. The resulting solutions were incubated for 0 h, 4h, 24 h and 48 h at 37 °C 
with continuous shaking (500 rpm) while still being protected from light. The plasma solutions were quenched with 2 mL 
methanol and the mixtures were centrifuged at 3000 rpm for 1 h at 4°C. The organic solvent was evaporated and the 
residue was dried overnight in vacuum. It was re-suspended in 100 µL of 1:1 (v/v) CH3CN/H2O solution, the suspension 
was filtered with 0.2 µm filters and analysed using HPLC (Agilent 1260).  
 
 
Photocytotoxicity Studies. Cells were seeded at a density of 4000 cells/well in 100 µL media and grown overnight in a 
humidified cell culture incubator at 37 °C and with 5% CO2. All experiments were performed in triplicates. The media 
was removed and replenished with varied concentrations of the Cr(III) complex diluted in appropriate volume of the 
culture media in a total volume of 200 µL. They were incubated for 4 h (or 24 h) and replaced with 200 µL of fresh 
culture media. Three of the plates were irradiated at 450 nm (dose: 7.6 J cm-2). Irradiation was performed in the 96-well 
culture plates using a LUMOS-BIO photoreactor (Atlas Photonics, Switzerland). Each well was individually illuminated 
with a 50 mW LED at constant current and the temperature of the plates was maintained constant at 37 °C with a 
cooling system. Total time of irradiation was 10 mins for HeLa, U87 and U373 cells, and 5 x 2 mins for RPE-1 with 15 
min intervals in between each irradiation. The cells were then allowed to grow in the incubator for another 44 h (or 24 h). 
In the three other plates for the dark cytotoxicity control, the media was removed after 4 h (or 24 h), replaced with 200 
µL of fresh culture media and incubated for another 44 h (or 24 h). After 48 h of the initial treatment, the media was 
exchanged for resazurin solution (0.2 mg mL–1) made in the respective culture media and sterile filtered. After 4 h 
incubation, the fluorescence of the product resorufin was measured at 590 nm with excitation at 540 nm using a 
Spectramax M5 UV-visible spectrophotometer. The data was analysed and plot using Graph Pad Prism 8. 
 
 
Lipophilicity Measurements. The lipophilicity of the Cr(III) complex was measured with respect to ferrocene in a PBS-
octanol system from the partition coefficient value (log P). The analytes were dissolved in DMSO to make a stock 
solution and then added to a 1:1 PBS/octanol pre-saturated mixture such that the final concentration was 200 µM and 
220 µM for ferrocene and the complex respectively. The mixtures were vortexed for 1 h and allowed to equilibrate at 
room temperature for another 2 h. The concentration in the two phases was determined by measuring the absorbance 
values at 445 nm and 435 nm for ferrocene and [Cr(ddpd)2]3 respectively using previously determined calibration 
curves. Lipophilicity values were calculated using the formula log{[C]oct/[C]aq} where Coct and Caq denote the analyte 
concentration in the octanol or the aqueous phase respectively. 
 
 
Confocal Microscopy. HeLa cells were grown in BioLite 35 mm confocal imaging glass dishes at a seeding density of 
5000 cells/ dish in DMEM supplemented with 10% FBS at 37 °C in 5% CO2. They were treated with [Cr(ddpd)2](BF4)3 
incubated for 4 h or 24 h. The media was removed and cells were washed thrice with PBS. They were further incubated 
with 2 drops per mL of media of NucBlue® Live ReadyProbes® for 30 mins at room temperature. Finally, cells were 
washed with thrice PBS and phenol free media (2 mL/ dish) was added. Live cell images were recorded using a Zeiss 
confocal microscope using excitation at 454 nm and emission filter was set at > 600 nm. 
 
 
Conductivity measurements. Conductivities were measured with a Greisinger conductivity cell, model 6MH 3431 LFE-
210 with platinum electrodes in the concentration range 10–6 – 10–4 M in dry acetonitrile under inert atmosphere. The 
equivalent conductivity Λe was plotted as a function of c0.5. To determine Λ0, Λe was extrapolated to infinite dilution. 
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